Stock Market & Financial Investment News

News Breaks September 7, 2012 09:12 EDT SNTS, PRX Santarus to benefit from removal of Par's generic Zegerid, says Roth Capital Roth Capital believes that Santarus' (SNTS) 2013 EPS could increase by 35c as a result of Par Pharmaceuticals' (PRX) decision to cease future distribution of the generic version of its Zegerid product. The firm thinks that Santarus could win a $1 per share cash settlement from Par and it maintains a Buy rating on Santarus. News For SNTS;PRX From The Last 14 Days Check below for free stories on SNTS;PRX the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 22, 2013 09:01 EDT PRX Par Pharmaceutical begins shipment of generic Atacand Subscribe for More Information May 17, 2013 10:36 EDT SNTS Leerink's major/specialty pharma analyst holds analyst/Industry conference call Subscribe for More Information May 10, 2013 09:06 EDT SNTS Santarus 4.25M share Spot Secondary priced at $18.25 Subscribe for More Information 09:00 EDT SNTS Santarus falls 7.3% Subscribe for More Information May 9, 2013 16:02 EDT SNTS Santarus files to sell common stock for Cosmo Technologies, no amount given Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.